The study is a phase 2 trial, which means it is an early study of the treatment in people with this disease. All participants receive the same treatment, and the study team follows what happens over time. The treatment is given in repeated cycles, and the medicines are continued while they are helping and side effects remain manageable. Doctors also monitor for side effects and other health changes during the study.

Participants are assigned to one of the study treatments and receive injections over time during regular study visits. The study team follows how the cancer responds and watches for side effects and other health changes. It also looks at how long the treatment effects last and how the treatments affect daily well-being and symptoms.

The purpose of the study is to see how well JNJ-79635322 works in people with this form of multiple myeloma. The study is open-label, which means everyone in the study receives the same treatment and knows what it is. Participants will receive the study medicine and be followed over time while the study team checks how the disease responds and watches for side effects.

This study is for people who have already had several previous treatments, including a PI, an IMiD, and an anti-CD38 antibody. A PI is a medicine that blocks a protein used by cancer cells to grow, an IMiD is a medicine that helps the immune system fight cancer, and an anti-CD38 antibody is a medicine that targets a protein on myeloma cells.

People in the study are assigned by chance to receive either AZD0120 or one of the standard treatment plans used for this disease. The standard plans may include combinations such as daratumumab, carfilzomib, bortezomib, pomalidomide, and dexamethasone. AZD0120 is given through a vein, while the other treatments may be given by infusion, injection, or as capsules or tablets taken by mouth. The study then follows participants over time to see how the disease changes, how long the treatment effects last, and how safe the treatments are, with regular checks of general health and blood tests.

The new treatment, Cesnicabtagene autoleucel, is a type of CAR T-cell therapy. This involves using T lymphocytes, which are a type of white blood cell that helps the body fight infection, that have been genetically modified in a lab to specifically target BCMA, a protein found on the surface of cancer cells. Participants in the study will receive either this modified cell therapy or a standard regimen consisting of other medications such as carfilzomib, daratumumab, cyclophosphamide monohydrate, dexamethasone, bortezomib, elotuzumab, or pomalidomide.

During the study, researchers will monitor how long patients live without their disease getting worse, known as progression free survival. Other aspects being observed include the overall response to the medicine, the presence of MRD-negativity, which means that very small amounts of cancer cells cannot be detected in the body, and the general safety and side effects of the treatments. The study also looks at how long the treatment remains effective and the overall quality of life for those involved.

The purpose of this study is to find out if treatment with linvoseltamab alone or linvoseltamab combined with carfilzomib works better than standard treatments for multiple myeloma that has returned or stopped responding to previous therapy. The study will measure how many patients have no signs of cancer cells remaining in their body after twelve months of treatment and how long patients live without their cancer getting worse. The study will also look at how safe these treatments are and what side effects patients may experience.

The study has two parts. In the first part, a small number of patients will receive linvoseltamab or linvoseltamab with carfilzomib to check that the dosing schedule is safe. In the second part, a larger group of patients will be randomly assigned to receive either linvoseltamab alone, linvoseltamab with carfilzomib, or standard treatment combinations. Patients will receive their assigned treatment in cycles lasting twenty-eight days. During the study, patients will have regular check-ups, blood tests, and other examinations to see how well the treatment is working and to monitor for any side effects. The study will also ask patients questions about their quality of life and how they are feeling.

The research is conducted in two stages. The first stage focuses on finding the correct dosage by gradually increasing the amount of the drugs to see how well they are tolerated. The second stage looks more closely at how well the combination of linvoseltamab and REGN17372 works to reduce the cancer, or how well linvoseltamab works when used by itself. During the study, participants may also receive background medications such as paracetamol for pain, diphenhydramine hydrochloride to manage certain symptoms, or dexamethasone, which is a type of steroid used to reduce inflammation.

Participants will receive the initial dose of teclistamab followed by regular injections and periodic infusions of their own lymphocytes over several months. Throughout the study, doctors will check the response of the disease at scheduled visits, monitor overall health, and watch for any side effects, including signs of cytokine release syndrome (a reaction that can cause flu‑like symptoms) and neurological changes known as ICANS (a type of brain inflammation). The overall period of observation will extend up to two years to assess how long the treatment benefits last and to ensure safety.

The purpose of the study is to evaluate how many participants experience a measurable reduction in their cancer using these combination therapies. Participants will receive the assigned medicines in cycles, attend regular clinic visits for blood checks, and undergo eye examinations because the investigational drug can affect the cornea, the clear front part of the eye. Terms such as “response rate” refer to the percentage of patients whose disease shrinks or disappears, while “adverse event” means any side effect that may occur, and “dose modification” means adjusting the amount of medicine if needed. The study will continue for several months, during which safety and effectiveness are closely monitored.

During the study, participants will receive these medications through different methods. Carfilzomib is given as an intravenous infusion, which is a liquid medicine delivered directly into a vein. Mezigdomide is taken as an oral capsule, and dexamethasone is provided both as an infusion and as an oral medication. The study follows the participants over a period of time to observe how the combination of these drugs affects the disease and how long the cancer remains stable before it begins to grow again.

The main purpose of this research is to determine the safest and most effective dose of mezigdomide when used together with elranatamab, and to understand how well this combination works in treating the disease. The study will look at how participants respond to the treatment and monitor any side effects that may occur.

During the study, participants will receive the combination treatment and undergo regular medical check-ups. Doctors will track how well the treatment is working by measuring the amount of cancer in the body and monitoring the participants’ overall health. They will also look at how long the treatment keeps working and how it affects participants’ survival.

The purpose of this study is to compare how well CT-P44 works compared to Darzalex Faspro, and how the body processes these medications. Both medications are given through subcutaneous injection, which means they are injected under the skin. The study is designed as a double-blind trial, meaning neither the patients nor the healthcare providers know which medication is being given.

During the study, participants will receive treatment for up to 104 weeks. The medications will be administered regularly according to a specific schedule, with a maximum daily dose of 1800 mg. Patients will be monitored throughout the treatment period to evaluate how well the medications work and to check for any side effects.

The purpose of the study is to determine if the new therapy works better than the standard treatments. Participants will receive either the new therapy or one of the standard treatments. The study will monitor how long participants live without their cancer getting worse and whether they achieve a state where no signs of cancer can be found in their body. The study will also look at overall survival, which is the average time participants are alive after starting the study, and how many participants show a positive response to the treatment.

Participants in the study will be adults who have received 1-3 previous treatments for Multiple Myeloma and have evidence that their disease worsened during or after their last treatment. The study will take place over several years, with an estimated end date in 2032. The goal is to find out if the new therapy can provide better outcomes for patients with this challenging condition.

The purpose of the study is to evaluate how well this combination works in elderly patients who have experienced a second or further relapse of their multiple myeloma. Participants in the study will receive either the treatment combination or a placebo. The study will monitor the participants over a period of time to see how their condition responds to the treatment. The treatment will be administered either orally or through an intravenous infusion, depending on the specific medication.

Throughout the study, researchers will track the overall response rate, which means they will look at how many participants show improvement in their condition. They will also observe how long the response lasts, the time it takes for the disease to progress, and the overall survival of the participants. The study aims to provide valuable information on the potential benefits of using Melflufen and Dexamethasone together for treating relapsed multiple myeloma in elderly patients.

The purpose of the study is to see how well anitocabtagene autoleucel works in helping patients live longer without their disease getting worse. Participants in the study will be randomly assigned to receive either the new treatment or one of the standard treatments. The study will monitor the participants over time to assess their response to the treatment, including how long they remain free from disease progression and their overall survival. The study will also look at the side effects of the treatments and how they affect the participants’ quality of life.

This trial is designed to provide valuable information about the potential benefits and risks of anitocabtagene autoleucel compared to existing therapies for relapsed/refractory multiple myeloma. The study will continue until enough data is collected to make a meaningful comparison between the treatments. The results of this study could help improve treatment options for patients with this challenging condition.

The purpose of this study is to evaluate how long patients can live without their disease getting worse while taking this combination of medications. Participants in the study will take these medications by mouth in specific doses over a period of time. The study will monitor the participants’ health and response to the treatment, including any side effects they may experience. The study will also look at how well the treatment works in terms of overall response and survival rates.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their condition. The study aims to provide valuable insights into the effectiveness of this treatment combination for patients with relapsed/refractory multiple myeloma. The results could help improve future treatment options for this challenging condition.

The purpose of the study is to evaluate how well these medications work together in treating patients with relapsed multiple myeloma. Participants in the study will receive these medications through intravenous infusions, which means the drugs are delivered directly into the bloodstream through a vein. The study will also include a process called autologous hematopoietic stem cell transplantation, where a patient’s own stem cells are used to help restore healthy blood cells after treatment.

Throughout the study, participants will be monitored to assess the response to the treatment and any side effects. The study aims to determine the rate of minimal residual disease (MRD) negativity, which indicates the absence of cancer cells in the body, within 12 months after the stem cell transplantation. The trial will also look at other outcomes, such as the overall response rate and the time it takes for the disease to progress. The study is expected to continue until early 2027.

The purpose of this study is to explore the safety and effectiveness of teclistamab in patients whose multiple myeloma has returned or has not responded to previous treatments. The study is divided into three parts. In the first part, different doses of teclistamab are tested to find the safest dose to use. In the second part, the focus is on understanding how well patients tolerate this dose. Finally, in the third part, the study looks at how effective teclistamab is in treating the disease.

Participants in the study will receive regular injections of teclistamab and will be monitored closely by the research team. The study aims to gather important information about how teclistamab works in treating relapsed or refractory multiple myeloma, which could lead to new treatment options for patients in the future.

The purpose of the study is to evaluate the safety and effectiveness of REGN5458 in patients with multiple myeloma who have already tried other treatments. The study is divided into two phases. In the first phase, the medication is given through an intravenous (IV) infusion to find the best dose that patients can tolerate. In the second phase, the study looks at how well the medication works in controlling the cancer. Some patients may also receive a pre-treatment with a medication that targets a protein called IL-6R to help manage side effects.

Throughout the study, participants will receive either the new treatment or a placebo. The study will monitor the participants’ response to the treatment, including any side effects they may experience. The goal is to determine if REGN5458 can be a safe and effective option for treating relapsed or refractory multiple myeloma. The study will continue until the researchers have enough information to make a conclusion about the treatment’s effectiveness and safety.

The purpose of this research is to find the best dose and schedule for using belantamab mafodotin together with bortezomib and dexamethasone to achieve good treatment results while reducing side effects. The treatment period may last up to 60 months, with regular monitoring of participants’ response to the medication combination.

During the study, participants will receive all three medications according to a specific schedule. The study team will monitor the effectiveness of the treatment and any potential side effects, particularly paying attention to effects on eye health. Regular check-ups and various tests will be performed throughout the study period to evaluate how well the treatment is working and ensure participant safety.

The medications being tested include Selinexor, Dexamethasone, and Bortezomib. Selinexor is a medication that works by blocking certain proteins in cancer cells, which can help stop the cancer from growing. Dexamethasone is a type of steroid that can help reduce inflammation and is often used in cancer treatment to help manage symptoms. Bortezomib is a drug that interferes with the growth of cancer cells and is used in the treatment of multiple myeloma. The study will also use a placebo in some cases to compare the effects of the actual medications.

The purpose of this study is to evaluate how well these medications work when used together in different combinations. Participants in the study will receive one of several treatment plans, which may include different doses of Selinexor and Dexamethasone, with or without Bortezomib. The study will monitor the participants over a period of time to see how their condition responds to the treatment. This will help researchers understand the effectiveness of these drug combinations in managing multiple myeloma.

The purpose of the study is to determine the safety and effectiveness of CC-92480 both on its own and when combined with dexamethasone. Participants in the study will receive the medication in capsule form, taken by mouth. The study will be conducted in two parts. In the first part, researchers will focus on understanding how the body processes the medication and identifying the best dose to use. In the second part, the study will expand to include more participants to further evaluate how well the treatment works in controlling the disease.

Throughout the study, participants will be monitored for any side effects and changes in their condition. The trial aims to provide valuable information on the potential benefits of CC-92480 for people with relapsed or refractory multiple myeloma, which could lead to new treatment options for this challenging condition. The study is expected to continue until early 2028, allowing researchers to gather comprehensive data on the treatment’s long-term effects and overall impact on the disease.

The purpose of the study is to evaluate how effective and safe bb2121 is for people with multiple myeloma that has either returned or not responded to previous treatments. In some cases, the study will also look at how well bb2121 works when used together with another medication called lenalidomide. Participants in the study will receive the treatment through an injection into a vein, known as an intravenous injection. The study will follow participants over time to see how their disease responds to the treatment and to monitor any side effects.

Throughout the study, researchers will collect information on how well the treatment works, including how long it takes for the disease to respond and how long the response lasts. They will also look at the overall health and quality of life of participants. The study aims to provide valuable information that could help improve treatment options for people with multiple myeloma in the future.

The purpose of the study is to see how well the new CAR-T cell therapy works compared to the standard treatments. CAR-T cell therapy is a type of treatment where a patient’s own immune cells are modified in a lab to better fight cancer cells. The study will involve participants receiving either the new therapy or one of the standard treatment combinations. The trial will monitor the participants over a period to see which treatment helps in delaying the progression of the disease.

Participants in the study will be randomly assigned to receive either the new CAR-T cell therapy or one of the standard treatment combinations. The study will take place over several months, and participants will be closely monitored by healthcare professionals. The goal is to determine which treatment is more effective in managing relapsed and resistant Multiple Myeloma. This research could potentially lead to new treatment options for patients with this challenging condition.

The purpose of the study is to evaluate the effectiveness of this combination treatment. Participants will receive the treatment over a period of time, and their response to the treatment will be monitored. The study will also look at how participants feel about the treatment method, particularly the use of a special device called the On Body Delivery System (OBDS) for administering isatuximab. This device is a single-use, wearable system that delivers the medication under the skin.

Throughout the study, researchers will observe various aspects of the treatment, such as the overall response rate, any side effects, and the duration of the response. The study aims to provide valuable information on how well this treatment combination works for people with relapsed and/or refractory multiple myeloma, and how it affects their quality of life. Participants’ experiences and satisfaction with the treatment will also be assessed through questionnaires. The study is expected to continue until December 2026.

Participants in the study will receive one of these treatments and will be monitored over a period of time to assess the treatment’s effectiveness and safety. The study will involve regular check-ups and assessments to track the progress of the disease and any side effects that may occur. The study is designed to provide valuable information on how these treatments compare in terms of helping patients live longer without the disease getting worse.

The trial will continue until the estimated end date in 2029, with recruitment of participants expected to start in 2024. This study is important for understanding better treatment options for people with Relapsed/Refractory Multiple Myeloma and aims to improve the quality of life and outcomes for those affected by this condition.

The study will involve participants receiving either the new treatment, bb2121, or one of the standard treatments. The new treatment, bb2121, is a type of cell therapy that uses a patient’s own immune cells, which are modified to better fight the cancer. The study will monitor how long patients live without their disease getting worse, which is known as progression-free survival. Other aspects being observed include the overall response to treatment, the duration of response, and the safety of the treatments.

Participants will be involved in the study for a period of up to 72 weeks, during which they will receive their assigned treatment and attend regular follow-up visits. The study aims to provide valuable information on the best treatment options for patients with relapsed and refractory Multiple Myeloma, helping to improve future care and outcomes for individuals with this condition.

The purpose of the study is to determine which treatment combination is more effective in managing the disease. Participants in the trial will be randomly assigned to receive one of the two treatment combinations. The study will monitor the participants over a period to observe how the disease progresses and to assess the safety of the treatments. The trial will also look at various outcomes, such as how long the disease remains under control, the overall survival of participants, and the quality of life during the treatment.

Throughout the study, participants will receive their assigned treatment and will be regularly checked by healthcare professionals to monitor their health and the effects of the treatment. The trial is designed to gather important information that could help improve treatment options for people with Multiple Myeloma in the future. Participants will be closely observed to ensure their safety and to collect data on how well the treatments work in controlling the disease.

The purpose of the study is to determine which treatment is more effective for patients with relapsed or refractory multiple myeloma, meaning the cancer has returned or is not responding to previous treatments. Participants in the study will receive one of the treatments mentioned above, and their progress will be monitored over time. The study will help researchers understand how well these treatments work in managing the disease and improving patient outcomes.

Participants will be randomly assigned to receive either the new treatment or one of the existing treatment combinations. The study will take place over a period of time, during which participants will be regularly assessed to track their response to the treatment. The main goal is to see how long patients can live without the disease getting worse, known as progression-free survival. This study is an important step in finding better ways to treat multiple myeloma and improve the quality of life for those affected by this condition.

The purpose of the study is to compare the effectiveness of these treatment combinations in managing the disease. Participants will be randomly assigned to one of the treatment groups and will receive their respective treatments over a specified period. The study will monitor the participants’ health and response to the treatments to gather data on how well each combination works. This will help in understanding which treatment option might be more beneficial for patients with this type of multiple myeloma.

Throughout the study, participants will undergo regular health check-ups and assessments to ensure their safety and to track the progress of their condition. The study is designed to provide valuable insights into the treatment of Relapsed or Refractory Multiple Myeloma and aims to improve the options available for managing this challenging condition.

Participants in the study will be randomly assigned to receive either Linvoseltamab or the combination of Elotuzumab, Pomalidomide, and Dexamethasone. The study will observe how long participants live without their disease getting worse, which is known as progression-free survival. The trial will also monitor other health outcomes, such as overall survival and the response of the disease to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments being studied.

The study will take place over a period of time, with regular check-ups and assessments to monitor the participants’ health and the effectiveness of the treatments. The goal is to gather information that could lead to better treatment options for people with Relapsed/Refractory Multiple Myeloma. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

The purpose of this study is to evaluate how safe and effective this new treatment is for patients with relapsed/refractory Multiple Myeloma. The study is divided into two phases. In the first phase, the focus is on determining the safety of the treatment and finding the right dose. In the second phase, the study will look at how well the treatment works in reducing the cancer. Participants will receive the treatment through an intravenous infusion, which means it will be given directly into the bloodstream through a vein.

Throughout the study, researchers will monitor participants for any side effects and measure how the cancer responds to the treatment. The study aims to provide valuable information on the potential benefits and risks of using BCMACP03 for treating relapsed/refractory Multiple Myeloma, with the hope of offering a new option for patients who have limited treatment choices. The study is expected to continue until 2027, allowing researchers to gather comprehensive data on the long-term effects and effectiveness of the treatment.

The main purpose of this study is to find the best dose of these medications when used together and to see how well they work in treating Multiple Myeloma that has come back after at least two previous treatments. The study is divided into two parts: the first part focuses on finding the right dose combination, while the second part looks at how effective this treatment is at controlling the cancer.

During the study, participants will receive the combination of medications and will be monitored regularly to check how their cancer responds to the treatment. The medications work in different ways to fight cancer cells: isatuximab targets specific proteins on cancer cells, evorpacept helps the immune system fight cancer cells, and dexamethasone helps reduce inflammation and supports the other medications’ effects.

The treatment involves receiving isatuximab through an intravenous infusion (directly into a vein), while pomalidomide is taken as capsules by mouth and dexamethasone as tablets. The study is divided into two parts – the first part finds the right dose of the new medications when combined with isatuximab, and the second part tests how well these combinations work in treating the cancer.

The study will measure how many patients respond to treatment and how much their cancer improves. It will also track how long the treatment works, how long patients survive, and what side effects may occur. Researchers will monitor patients’ quality of life during treatment using special questionnaires and collect blood samples to study how the medications work in the body.

The purpose of this study is to find the right dose of these medications when used together and to see how well they work in treating Multiple Myeloma that has come back or is not responding to other treatments. The study is divided into two parts: first, researchers will determine the best dose of the medications, and then they will test how well this combination works in more patients.

During the study, participants will receive the combination of these medications. The treatment will continue as long as it is helping the patient and any side effects can be managed. Researchers will monitor how the cancer responds to the treatment and track any side effects that may occur. They will also look at how the medications work in the body and assess how the treatment affects patients’ quality of life.

The purpose of this research is to evaluate how well these medications work together in treating patients whose cancer has previously been treated with other therapies. The study is divided into two parts. The first part will determine the right dose of the medications when used together, while the second part will test how effective this combination is in treating the cancer.

During the study, participants will receive both medications through regular infusions. The treatment will continue as long as it appears to be helping and the side effects are manageable. Throughout the study, doctors will monitor participants’ health status and how well the cancer responds to treatment. They will also assess how the treatment affects participants’ quality of life.

The purpose of this research is to find the most effective and safe dose of these medications when used together in treating multiple myeloma that has returned or not responded to at least two previous treatments. The study is divided into two parts – the first part will determine the right dose of the medications, and the second part will test how well the combination works at the chosen dose.

During the study, participants will receive the medications through different routes – isatuximab and belantamab mafodotin will be given through an intravenous infusion (directly into a vein), while dexamethasone will be taken as tablets by mouth. The study will monitor how participants respond to the treatment and track any side effects that may occur.